Huan Zhong

Huan Zhong


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Hepatology Communications
Verified
Journal Article
Open access
RZRuhan Zhang
Ruhan Zhang
ZYZhaobo Yan
Zhaobo Yan
HZHuan Zhong
Huan Zhong
RLRong Luo
Rong Luo
WLWeiai Liu
Weiai Liu
MLMi Liu
Mi Liu
With an increasing prevalence, metabolic dysfunction–associated steatotic liver disease (MASLD) has become a major global health problem. MASLD is well-known as a multifactorial disease. Mitochondrial dysfunction and alterations in the gut bacteria are 2 vital events in MASLD. Recent studies have highlighted the cross-talk between microbiota and mitochondria, and mitochondria are recognized as pivotal targets of the gut microbiota to modulate the host's physiological state. Mitochondrial dysfunction plays a vital role in MASLD and is associated with multiple pathological changes, including hepatocyte steatosis, oxidative stress, inflammation, and fibrosis. Metabolites are crucial mediators of the gut microbiota that influence extraintestinal organs. Additionally, regulation of the composition of gut bacteria may serve as a promising therapeutic strategy for MASLD. This study reviewed the potential roles of several common metabolites in MASLD, emphasizing their impact on mitochondrial function. Finally, we discuss the current treatments for MASLD, including probiotics, prebiotics, antibiotics, and fecal microbiota transplantation. These methods concentrate on restoring the gut microbiota to promote host health.

1 January 2023 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
ZLZhiyi Liang
Zhiyi Liang
QFQianzeng Fu
Qianzeng Fu
HLHaiman Li
Haiman Li
XXXuan Xu
Xuan Xu
PDPanting Ding
Panting Ding
MLMi Liu
Mi Liu
Objective. From the perspective of metabolomics, this study compares the metabolomics characteristics of feces and urine between children with spleen‐deficiency and healthy children to explain the scientific connotation of children with spleen‐deficiency susceptibility to digestive system diseases from the metabolic level and provide a scientific basis for further research. Methods. This study included 20 children with spleen‐deficiencies and 17 healthy children. Children’s symptom scores, height, and weight were recorded in groups, and feces and urine samples were collected. The samples were detected using ultrahigh‐performance liquid chromatography‐mass spectrometry. The data were analyzed using multivariate statistical analysis such as principal component analysis (PCA) and partial least squares discriminant analysis (PLS‐DA). Related differential metabolites were identified through database comparisons between two groups based on the MS and KEGG. Results. Compared to healthy children, the metabolites glucuronic acid, xanthine, and indole‐3‐acetaldehyde tend to be reduced in children with spleen‐deficiency. Moreover, these children showed an increase in metabolites such as quinic acid, adenine, 4‐methyl‐5‐thiazole‐ethanol, 3‐formyl indole, and 5‐hydroxy indole‐3‐acetic acid. The condition affected many of the critical metabolic pathways, including the metabolism of tryptophan, cysteine, methionine, and pentose phosphate. Conclusion. The children with spleen‐deficiency had disorders at the metabolic level, which might be due to factors such as diet, personal preferences, and genes, leading to various symptoms, making spleen‐deficiency children more prone to suffer from digestive diseases than healthy children. The results set a basis for the research on children’s TCM constitution, which can be a reference to further studies to deal with the spleen‐deficiency.

13 April 2026
Verified
Book Chapter
Open access
PDF file
MLMi Liu
Mi Liu
HXHaihua Xie
Haihua Xie
SCSihui Cao
Sihui Cao
JJJia Jiang
Jia Jiang
WLWeiai Liu
Weiai Liu
PLPenghui Lu
Penghui Lu
Functional dyspepsia (FD) is a common functional gastrointestinal disorder that can be classified into two subtypes: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Although this disease does not increase mortality, its symptoms significantly reduce patients’ quality of life and impose a heavy economic burden on both society and individuals due to frequent medical visits and decreased productivity. To alleviate physical and mental distress, many patients turn to complementary and alternative medicine (CAM). However, given the diversity of CAM therapies, their safety and efficacy still require conclusive evidence for validation; if proven effective, they are expected to be incorporated into the standard treatment regimen for FD. Currently, methods such as traditional Chinese medicine, acupuncture, moxibustion, massage, and dietary therapy have demonstrated the potential to alleviate FD symptoms and improve patients’ health conditions. Therefore, obtaining high-quality evidence regarding their efficacy and safety through randomized controlled trials (RCTs) is crucial for promoting the widespread application of CAM. This section will provide an overview of the clinical trial findings and underlying mechanisms related to CAM.